cyrilzakka/clinical-trials huggingface dataset:
BEETROOT JUICE INTAKE in POSTMENOPAUSAL HYPERTENSIVE WOMEN

The goal of this clinical trial is to verify the hemodynamic and biomarker responses of beetroot juice intake in postmenopausal women with hypertension. The main questions it aims to answer are:

Is beetroot juice dose related to better hemodynamic responses in hypertensive postmenopausal women? Is beetroot juice dose related to better oxidative stress profile responses in hypertensive postmenopausal women?

The investigators will conduct a parallel clinical study with 10 days of intervention, in which 48 women will be randomized into 3 groups: 1) Two shots of beetroot juice intake per day (800mg of NO3-); 2) One shot of beetroot juice intake per day (400mg of NO3-); 3) placebo intake (beetroot juice without NO3-).

The entire intervention will take place at the Physical Education campus of University, in the Cardiorespiratory and Metabolic Physiology Laboratory (LAFICAM). The recruitment and approach of the volunteers will occur through media dissemination, such as radio announcements, television programs, and social media through digital media. After the dissemination, volunteers will make contact via phone, email, or social media, and a preliminary registration will take place. After this registration, the researchers will verify which volunteers meet the inclusion criteria, and only then will the recruitment take place.

The volunteers will be invited to come to LAFICAM to be informed about the intervention program and then sign the informed consent form. Before starting the intervention program, all volunteers must present a medical certificate clearing them to participate in a physical exercise training program; once the certificate is submitted, initial tests and general evaluations will be conducted.

The initial evaluations will consist of a questionnaire, anthropometric and body composition assessment, and evaluation of the physical activity level. After the questionnaires are administered, a familiarization with the sensory perceptions of beetroot juice will be conducted. This familiarization is important to verify if the volunteers are fit to carry out the intervention.

The volunteers will be randomized into three groups: Group 1: the volunteers will ingest two shots containing 70 ml of beetroot juice with 400 mg of nitrate per day, one shot in the mornig and one shot at night, for 10 days; Group 2: this group will intake 70 ml of beetroot juice with 400 mg of nitrate every morning.

Group 3: this group will intake 70 ml of beetroot juice without nitrate for 10 days.

Eligibility Criteria:
Inclusion Criteria:

* Amenorrhea for at least 12 months
* Controlled hypertension

Exclusion Criteria:

* Decompensated hypertension in stages 2 and 3
* Having a history of stroke or acute myocardial infarction
* Smoker
* Having a diagnosis of Diabetes Mellitus
* Using hormone therapy.
Immediate Effects of Ankle MWM and Taping on Gait and Balance in Stroke Patients

Disorders caused by stroke may lead to significant limitations, especially in ankle range of motion, and may cause impairments in walking and balance functions. This limitation in ankle range of motion leads to difficulties in weight transfer, stability, and balance. As a result, there is a decrease in walking performance and an increased risk of falls. Various interventions have been used to improve ankle dorsiflexion passive range of motion, including gastrosoleus muscle stretching, muscle strengthening training, functional electrical stimulation training, proprioceptive control training, taping, manual therapy, different mobilization techniques, and ankle mobilization with motion (MWM).There are limited studies investigating the immediate effects of MWM and taping on gait and balance in stroke patients. This study was planned to investigate the effect of Mulligan's ankle MWM technique and talus stabilization taping on spatiotemporal gait and balance parameters in stroke patients.


Eligibility Criteria:
Inclusion Criteria:

1. Having a unilateral stroke for more than three months,
2. Being able to walk 10 meters without an assistive device,
3. Being able to walk unassisted before having a stroke,
4. Having a score of 3 or lower on the Modified Ashworth Scale (MAS),
5. Be able to follow simple verbal instructions,
6. Being Volunteer

Exclusion Criteria:

1. Having had more than one stroke,
2. Cerebellar involvement,
3. Having severe visual impairment,
4. Having cognitive impairment,
5. Severe aphasia,
6. Apraxia,
7. Having contraindications for joint mobilization (e.g. ankle hypermobility, trauma, inflammation),
8. Have significant lower limb problems such as fractures or arthritis,
9. Having undergone musculoskeletal surgery less than 6 months ago,
10. Having joint contracture in the paretic ankle that prevents walking.
Potency of Topical Corticosteroids in Combination Preparations

Several combination topical drugs are available on the market. The potency of corticosteroids depends on a particular molecular structure and the skin penetration properties. Besides molecular structure, a penetration of a corticosteroid molecule correlates with physical properties of the vehicle which depend on physical properties of the vehicle constituents.

Vasoconstriction assay is considered as the gold standard for testing potency of topical corticosteroids.

Primary outcome: Change in Vasoconstriction index following application of topical corticosteroids that are incorporated with or without an antibiotic and/or antifungal drugs in healthy volunteers.

Eligibility Criteria:
Inclusion Criteria:

* No prior history of internal diseases that required vaccine-suppressing treatments
* Absence of an active skin disease.

Exclusion Criteria:

* Treatment with topical corticosteroids in the 4 weeks prior to the study
* Immune-suppressive treatment in the 4 weeks prior to the study
* Pregnancy or breast feeding
Effect of Deep Brain Stimulation on Gastrointestinal (GI) Motility

Parkinson's disease is characterized by extra-pyramidal symptoms as well as digestive involvement with gastrointestinal motility (GI) impairment. Deep brain stimulation has been recently developed as a successful treatment for extrapyramidal symptoms. In addition, preliminary reports suggest that this therapy might be successful to relieve GI symptoms as well. The aim of this study is therefore to assess the effect of deep brain stimulation on GI voluntary as well as involuntary motility.


Eligibility Criteria:
Inclusion Criteria:

* patient over 18 yo
* patient with Parkinson's disease implanted for deep brain stimulation
* patient responders to deep brain stimulation (UPDRS improved by at least 40%)
* patient covered by the french health care system
* patient not taking anti-parkinsonian medication the day before evaluation
* French speaking

Exclusion Criteria:

* patient below 18 yo
* pregnancy
* Severe psychiatric or cognitive disorders
* diabetes mellitus
* morbid obesity
* compulsive eating disorders
* diffuse GI motility impairment (except Parkinson's disease)
* other evolutive neurologic disorders
* previous history of significant GI resection
* inability to swallow or defecate when asked
IGFBP-3 in Ovarian Cancer Invasion

An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as an invasion-suppressor gene. We plan to study the role of IGFBP-3 in ovarian cancer invasion.

We have successfully established an ovarian cancer cell line (OVTW-59), which was derived from an ovarian endometrioid carcinoma. Its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities, were selected from transwell invasion chambers, where P0 represented the original cell line at 100th passage. By using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified the differentially gene expression profiles of these OVTW-59 series cell lines in order to identify the invasion related suppressor and oncogenes from ovarian carcinoma. From these genes, we selected insulin-like growth factor binding protein (IGFBP)-3, which is a suppressor gene, and found it lower expressed in higher-grade tumors and correlated with poor patient survival. In vitro, we found IGFBP-3 related to the inhibition of cancer cell migration. In this study, we plan to setup stable transfected IGFBP-3 cell lines in P0 and P4, and study the relationship among IGFBP-3, metalloproteinase-2 (our previous studies which verified its relationship with tumor invasiveness) and insulin-like growth factor (IGF)-1. We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3. Furthermore, we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasion/migration of ovarian carcinoma, either signaling through MAPK or PI3K/AKT pathways. Finally, through xenograft, we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy.

Eligibility Criteria:
Inclusion Criteria:

Ovarian Endometrioid Adenocarcinoma

Exclusion Criteria:

Other types of ovaria epithelial cell carcinoma
Effect of Cinematic Simulation on Emotions, Resilience, and Empathy Among Undergraduate Nursing Students

The aim of this study is to:

Determine the effect of cinematic simulation as action to regulate emotions, leverage resilience, and foster empathy among undergraduate nursing students.

Research Hypothesis Nursing students who participated in cinematic simulation will exhibit better regulation of emotions, resilience, and empathy than those in the control group

The current study's population was the second-term "4th level" registered undergraduate nursing candidates in the year 2022/2023.

A sample of 70 randomly selected students from the psychiatric nursing rotation will be included in this study. The study subjects will be divided equally into two groups (study and a control group) matched as much as possible. The exclusion criteria include students who were not willing to participate in the study, those who complained of any mental disorders or had a previous history of any mental problems.

Assigned students will be randomly divided into two groups of intervention; study (n = 35) and control (n = 35). The control group will receive usual training based on the educational objectives of routine methods of lectures, discussion, ...etc.

The study group (35 students) will be divided into 7 small groups of (5 students in each group). In addition to routine training provided for the control group, the students of the intervention group will be provided with micro learning content following the educational topics of the course in the form of short videos of cinematic films reinforcing values of resilience, empathy, and positive emotions in dealing with others.

Objectives for the cinematic simulation included the following: 1) apply the principles of positive emotions, empathetic understanding and resilience to students from diverse backgrounds; 2) analyze the care management process as it relates to assessment, goals, interventions, teaching, and outcomes in mental health nursing; and 3) Reinforcing the psychological role of the professional nurses in caring for patients with different diagnoses.

Eligibility Criteria:
Inclusion Criteria:

* Egyptian Nursing students

Exclusion Criteria:

complained of any mental disorders or had a previous history of any mental problems.
Lipid Based Food Additives for Treating Patients With Dry Mouth

Over 10% of adult population suffers from dry mouth (xerostomia). The aim of this double blind prospective clinical trial is to examine a new lipid based food additive formulation to ease mouth dryness in these patients.


Eligibility Criteria:
Inclusion Criteria:

* Dry mouth patients

Exclusion Criteria:

* Disabled patients
* Pregnant
* Full upper denture
* Under 18 years old
Health Behaviors and Time-of-Day: Older Adult Cognitive Function

This is a single-center, observational study design. Enrolled participants will be typically, healthy older adults. Participants will complete daily computerized measures, in addition to continuously wearing an Actiwatch device. The study period will last 2 weeks. The objectives of the study are to examine the impact of sleep, pain, and circadian rhythm on practice-related learning in older adults at their preferred versus nonpreferred times of day.

Participants will be asked to review the informed consent and consent to the study prior to any study procedure.

There are four stages to this study: 1. a telephone interview, 2. an in-person interview and completion of questionnaires, 3. an in-home single night sleep recording, and 4. two weeks of computerized cognitive testing, subjective sleep and pain recordings, and wearing a Actiwatch.

During the telephone interview, participants will be asked question about their age, sleep, pain, and medical/mental health history. At a second visit, participants will complete a more in-depth interview of their physical health, mental health, sleep, and pain history. They will complete a brief test of their cognitive functioning. They will also complete 4 questionnaires about their time of day preference and mood. At the third visit, participants will visit the University of Florida to be connected to a machine which will monitor their sleep. Participants will return home to sleep while still connected to the machine and will return the machine to the University of Florida the next day. Participants will complete brief computerized daily questionnaires of sleep and pain and cognitive testing in the morning and evening, and and wear an actigraph (wristwatch-like device) that measures arm movements and ambient light for two weeks.

Eligibility Criteria:
Inclusion Criteria:

* Age of 65 years and older
* Able to read and speak English
* Completion of Morningness-Eveningness Questionnaire

Exclusion Criteria:

* Significant medical or neurological disorder
* Major psychopathology
* Pain disorder other than fibromyalgia or osteoarthritis
* Sleep disorder other than insomnia
* Cognitive impairment
* Psychotropic or other medications known to alter sleep
* Unable to provide informed consent
Cardiovascular Effects of Metformin on Obesity

It has been shown that asymptomatic obese adolescents can demonstrate abnormal regional myocardial contraction, with preserved global cardiac function. Metformin has been shown to decrease cardiovascular mortality in patients with type 2 diabetes and insulin resistance, but the mechanism of cardiovascular protection is unknown.

The purpose of this study is to evaluate the reversibility of subclinical cardiovascular abnormalities in obese adolescents with insulin resistance after a six-month course of Metformin. The investigators hypothesized that the beneficial effects of Metformin will be progressive and sustained after six months of therapy.


Eligibility Criteria:
Inclusion Criteria:

* Adolescents 12 to 17 years old under clinical care at the UCSF WATCH clinic
* Body mass index\> 95th percentile for age and gender according to the Centers for Disease Control and Prevention 2000 growth charts for the United States
* Insulin resistant after 6 months of healthy diet and exercise
* Able to understand the assent form

Exclusion Criteria:

* Patients with known cardiac disease
* Patients with contraindications to metformin as listed below:

  * Renal disease or renal (serum creatinine levels ≥1.5 mg/dL for males, and ≥1.4 mg/dL for females;
  * Known hypersensitivity to Metformin;
  * Acute or chronic metabolic acidosis;
* Patients with contraindications to MRI including:

  * Cardiac pacemaker;
  * Claustrophobia;
  * Metallic foreign body in the eye,
  * Aneurysm clip in the brain
* Pregnancy;
* Patients who could not stay still for 30 minutes within the MRI scanner due to other reasons besides claustrophobia
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

The purpose of this study is to test the safety and efficacy of OMP-336B11. OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.

This is an open-label, Phase 1a dose escalation study of OMP-336B11 administered as a single agent to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with locally advanced or metastatic tumors. This study consists of a screening period, a treatment period, and a post-treatment follow-up period in which patients will be followed for survival for up to approximately 2 years. Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase.

Eligibility Criteria:
Inclusion Criteria:

* Locally advanced or metastatic solid tumors that have exhausted standard of care therapy
* Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
* Age \>21 years
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate organ and marrow function
* For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Receiving any other investigational agents or any other anti-cancer therapy
* Active autoimmune disease or a history of severe autoimmune disease or syndrome
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
* Pregnancy, lactating or breastfeeding women
* History of primary CNS malignancy, or leptomeningeal disease or CNS metastases
* Significant uncontrolled intercurrent illness that will limit the patient's ability to participate in the study
* Inability to comply with study and follow up procedures
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)

The purpose of this study is to assess UDFF performance (compared to MRI)


Eligibility Criteria:
Inclusion Criteria:

* All patients who had hepatic ultrasound with available UDFF measurements and hepatic MRI (with steatosis quantification sequences) between 01/01/2022 and 31/09/2023 may be included.

Exclusion Criteria:

* chronic liver disease with a different etiology other than NAFL/NASH or mixed (hepatitis B or C, hemochromatosis, autoimmune hepatitis, Wilson's disease, cholestasic disease, alpha 1 antitrypsin deficiency),
* decompensated cirrhosis (ascites, jaundice, encephalopathy, rupture of esophageal varices),
* hepatocellular carcinoma.
* opposition to the use of its data
Decision-making and Risk-taking in Bulimia

This trial is a set of four independent experiments involving for each of them functional and structural MRI data acquisition. They aim at investigating decision making mechanisms in bulimia nervosa when participants have to make food or monetary choices under specific conditions that mimic binge eating episodes or kleptomania which are two major symptoms of bulimia nervosa. All experiments are cross sectional studies. Each experiment is subdivided into two parts: a first part without any MRI data acquisition and during which all the tasks are performed. This part aims at making sure that a behavioral effect is observed before starting MRI data acquisition. The second part aims at investigating the neural correlates observed in the first part and additionally, at reproducing the behavioral effects observed in the first part. Therefore the first part may be regarded as an independent study as compared to the second part.

Each part of each experiment is built of a main task, a set of secondary tasks and questionnaires. Only the main task changes from one experiment to another. Within each experiment, the only difference between the two parts is that the main task is performed while participants are being scanned in an MRI scanner. Details of the tasks are provided below. Each part of each experiment is performed over one visit only and is a cross sectional study. The visit is dedicated to the tasks. Questionnaires may be filled during the visit or at participant's home within the week following the visit for questionnaires which are not assessing participant's state. Questionnaires assessing participant's state are filled during the visit at appropriate time. The total number of participants mentioned below is the sum of the planned number of participants within each group, i.e. patients and healthy participants, within each part of each experiment.

Eligibility Criteria:
Inclusion Criteria:

* men and women aged 18 to 35 years with bulimia nervosa according to DSM 5 criteria for the patient's group
* For the control group, men and women with the same age range being concerned by food intake and their body shape but without any history of eating disorder.
* All participants must have signed an informed consent form and be affiliated to the French public health insurance.
* for MRI scans, all participants must be right handed.

Exclusion Criteria:

* antisocial personality disorder,
* borderline personality disorder
* addiction to alcohol or psychoactive agent, ADHD, any psychotic disorder,
* obesity of class 1 or 2
* istory of psychiatric disorder for the control group
* history of neurological disorder for both groups
* intermittent explosive disorder
* any counter indication to MRI scans for the parts of experiments which take place in the MRI scanner.